glp-1 vision loss ema recommendation november 2025 Possible Link Between RA Medications & Eye Health ADA '26: Lilly's dominance, Pfizer's
Description
Sensitivity analysis To assess the robustness of our findings, we conducted leave-one-out sensitivity analyses for the primary and secondary outcomes
Comparing oral GLP-1 frequency with newer formulations The GLP-1 landscape is evolving rapidly
Blood pressure measurement is essential
In July 2023, the EMA initiated an inquiry into safety concerns after receiving approximately 150 spontaneous reports indicating potential links between drugs and suicide ideation or self-harm [72]
, GLP-1
